Skip to content
OpenCapital
Get started

Johnson & Johnson JNJ Innovative Medicine — Sales to customers (Note 9)

Other segment segments

MEDTECH
$8.64B+7.7%

Similar metrics at other companies

DXP Enterprises logo
DXPEInnovative Pumping Solutions — Revenue change
$32.48M—
DXP Enterprises logo
DXPEInnovative Pumping Solutions — Sales
$118.66M+37.7%
Bioventus logo
BVSInternational Segment — Total Net Sales
$15.64M+17.1%
Aveanna Healthcare Holdings Inc. logo
AVAHMedical Solutions — Revenue
$45.65M+7.4%
NAG
NAGEPharmaceuticals segment — Sales, net
$0—
Pulmonx Corporation logo
LUNGOther International — Revenue
$51K+34.2%

Other financials

Income statement

See full
Revenue$24.1B+9.9%
Gross profit$16.0B+9.8%
Operating income$6.3B+2.3%
Net income$5.2B-52.4%
EPS (diluted)$2.14-52.9%

Balance sheet

See full
Cash & equivalents$21.7B-43.6%
Total debt$55.0B+5.2%
Total equity$81.2B+3.9%
Total assets$200.89B+3.7%

Cash flow

See full
Operating cash flow$2.5B-39.8%
CapEx$1.0B+31.9%
Free cash flow$1.5B-56.6%

Valuation

See full
Market cap$623.71B+66.9%
Enterprise value$657.01B+61.9%
P/E29.6×+13.2×
P/S6.5×+2.3×

Profitability

See full
Gross margin67.8%-0.5pp
Operating margin26.4%+2.8pp
Net margin21.8%-2.6pp
FCF margin18.5%-4.3pp

Returns & leverage

See full
Return on equity26.4%-3.0pp
Debt / equity0.7×0.0×
Current ratio1×-0.2×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Johnson & Johnson’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →

Ask your AI about Johnson & Johnson's innovative medicine — sales to customers (note 9).

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Johnson & Johnson's innovative medicine — sales to customers (note 9)?
Johnson & Johnson (JNJ) reported innovative medicine — sales to customers (note 9) of $15.43B in Q1 2026.
How has Johnson & Johnson's innovative medicine — sales to customers (note 9) changed year-over-year?
Johnson & Johnson's innovative medicine — sales to customers (note 9) increased by 11.2% year-over-year, from $13.87B to $15.43B.
What is the long-term trend for Johnson & Johnson's innovative medicine — sales to customers (note 9)?
Over 4 years (2021 to 2025), Johnson & Johnson's innovative medicine — sales to customers (note 9) has grown at a 4.0% compound annual growth rate (CAGR), from $51.68B to $60.4B.
What does innovative medicine — sales to customers (note 9) mean?
Measures the total revenue generated from external customers by the Innovative Medicine segment. This is the primary top-line metric for the segment, representing the market demand for its pharmaceutical products and therapies. It excludes inter-segment transfers to provide a clear view of the segment's external market performance.